for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Epizyme Inc

EPZM.OQ

Latest Trade

11.41USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.92

 - 

27.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.41
Open
--
Volume
--
3M AVG Volume
19.20
Today's High
--
Today's Low
--
52 Week High
27.79
52 Week Low
9.92
Shares Out (MIL)
101.58
Market Cap (MIL)
1,149.90
Forward P/E
-5.04
Dividend (Yield %)
--

Next Event

Q4 2020 Epizyme Inc Earnings Release

Latest Developments

More

Epizyme Reports Q3 Loss Per Share $0.55

Epizyme Reports Q2 Loss Per Share $0.58

Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Epizyme Inc

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Industry

Biotechnology & Drugs

Contact Info

400 Technology Sq Ste 4

CAMBRIDGE, MA

02139-3584

United States

+1.617.2295872

http://www.epizyme.com/

Executive Leadership

David M. Mott

Independent Chairman of the Board

Robert B. Bazemore

President, Chief Executive Officer, Director

Paolo Tombesi

Chief Financial Officer

Jeffery L. Kutok

Chief Scientific Officer

Shefali Agarwal

Chief Medical Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.180

2018

-1.720

2019

-1.930

2020(E)

-2.246
Price To Earnings (TTM)
--
Price To Sales (TTM)
98.44
Price To Book (MRQ)
5.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
33.65
LT Debt To Equity (MRQ)
33.65
Return on Investment (TTM)
-68.08
Return on Equity (TTM)
-61.98

Latest News

Latest News

BRIEF-Epizyme To Present Data From Tazemetostat Clinical Program During 2020 ASCO Virtual Scientific Program

* EPIZYME TO PRESENT DATA FROM TAZEMETOSTAT CLINICAL PROGRAM DURING THE 2020 ASCO VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Epizyme Posts Q1 Loss Per Share Of $0.51

* EPIZYME REPORTS BUSINESS PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Epizyme Appoints Jeffery Kutok As Chief Scientific Officer

* EPIZYME APPOINTS JEFFERY KUTOK, M.D., PH.D., AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Epizyme Reports Fourth Quarter Loss Per Share Of $0.59

* EPIZYME PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Epizyme Announces FDA Acceptance Of NDA For Filing With Priority Review For Tazverik (Tazemetostat) For The Treatment Of Follicular Lymphoma

* EPIZYME ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR FILING WITH PRIORITY REVIEW FOR TAZVERIK™ (TAZEMETOSTAT) FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

Epizyme prices rare tissue cancer treatment at $15,500 a month

Epizyme Inc on Thursday priced its treatment for a ultra rare, slow growing type of cancer that affects soft tissue at $15,500 per month after getting an approval from the U.S. Food and Drug Administration.

FDA approves Epizyme's treatment for rare tissue cancer

The U.S. Food and Drug Administration has approved Epizyme Inc's treatment for a rare, slow growing type of cancer that affects the soft tissue, the company said on Thursday.

CORRECTED-BRIEF-Epizyme Reports Q3 Loss of $0.54 Per Share

* EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS

BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49

* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Epizyme Provides Update Regarding Tazemetostat Clinical Program

* EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM

BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed

* EPIZYME INC FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/2q8HM38) Further company coverage:

BRIEF-Epizyme Q4 Loss Per Share $0.52

* EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up